AstraZeneca To Stop Selling of Covid-19 Vaccine Globally

The Covid-19 vaccine is being withdrawn globally by AstraZeneca because there has been a “oversupply of available updated vaccines” since the epidemic. “As multiple, variant Covid-19 vaccines have since been developed, there is a surplus of available updated vaccines,” the business said, citing the Reuters news agency. It also added that this had caused a fall in demand for Vaxzevria, which is no longer produced or provided.

The UK-based pharmaceutical behemoth recently acknowledged that, although the cause is unknown, the Covid vaccination may occasionally result in a side-effect relating to blood clots in “extremely rare cases.”

According to The Daily Telegraph, AstraZeneca acknowledged that the vaccine it developed with the University of Oxford to protect against Covid-19 may, in “very rare cases,” cause thrombosis with thrombocytopenia syndrome (TTS) in a court filing submitted to the High Court in London in February for a group action filed by 51 claimants.

Known as Covishield in India, the AstraZeneca Vaxzevria vaccine was produced by the Serum Institute of India as well.

A petition was filed in the Supreme Court last week asking for an order to establish a panel of medical experts to review the side effects of the Covishield vaccination.

In addition to making the motion, advocate Vishal Tiwari sought the court to order the Centre to set up a vaccine damage payout scheme for the individuals who were rendered severely incapacitated during the pandemic campaign immunisation drive.

In the plea, advocate Vishal Tiwari requested that a panel of medical experts from the All India Institute of Medical Science, Delhi, be assembled. The panel would be led by the director of the institute and overseen by a retired justice of the Supreme Court of India. The panel’s purpose would be to investigate the potential side effects and risk factors associated with the Covishield vaccine.

According to lawyer Vishal Tiwari, more than 175 crore Covishield dosages have been given in India. According to the appeal, advocate Tiwari stated that there has been a rise in heart attack and abrupt collapse deaths since COVID-19.

Lawsuits are also being filed against Serum Institute of India (SII), which manufactures AstraZeneca’s COVID-19 vaccine in India under the trade name Covishield.